Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
imo with the daily volume under 400k the company isn't selling shares
Glta
I'm so happy to see the yesterday 8-k form ( http://ih.advfn.com/p.php?pid=nmona&article=43259595&symbol=NB^EFIR )
in the 8K form is written:
"... I.Purchase of Stock and Purchase Price
1.The Company agreed to pay to the Sellers aggregate consideration delivery of:
(a) 22,946,859 shares of the Company’s common stock issued to the Sellers pro rata based on their ownership in CHANWEST representing $95,000 in value ("STOCK CONSIDERATION").
and
... II. Purchase Price Adjustment Mechanism
1. Of the shares to be issued to Sellers by the Company, ten percent (10%), or 2,294,686 shares shall be held back and not issued for a period of one hundred twenty (120) days from Closing (the “holdback period”) and shall thereafter be issued to Seller subject to the following conditions having been met within the holdback period. ...
and
... Additional services of Chanwest include marketing for its workover rig having pulling capacity for wells to 6000’ feet depth. It will be used with a crew on our own leases in our second phase of operations planned, along with our current status of workover rig for hire to operators.
Chanwest estimates approximately 2 million in gross revenues from operations over the next year.
For its third phase of operations the Company’s newest wholly owned subsidiary Chanwest will work alongside Energy Producers unit operations to evaluate potential for acquisitions and development strategies for the production of oil and gas operations, initially working towards acquiring strategic rehabilitation targets in and around Abilene and other areas in Texas. .... "
If i understand the those statments EFIR has bought Chanwest for about 22.95M shares representing $95,000 in value. This means that the price for a share is 95,000$/22,946,859 = 0,00414$ so the seller (company ore some other) who has sold shares from 0.0082 till 0.0040 has made some profit. This explain why the pps droped till 0.004$. At that point the seller had no profit.
So about 20M shares were sold at open market other 2.3M can be sold after 120 days .This imo explain this crazy volume of 10M for 2 straight days. If the average seeling pps was at 0.007$, this is worth: 20M shaers x 0.007$ = about 140.000$ (which rapresents another 50,000$ profit for the seller)
So EFIR bought Chanwest (estamiates 2M in gross revenue) for about 96,000$ .. imo this is a good deal if the estimates of Chanwest are true. Correct me if i'm wrong!
Good luck
Loonley Tunes
Before you buy something do a good DD and make your own conclusions. My post express only my oppinion.
imo the sellers at 0.013 is all profit taking from 0.010$.
I like all those buys at 0.0149$ before the sell at 0.013 get trough.
Hope we start going up at that point.
i'm so happy of this 0.015 close in combination with 380k volume.
Hope in another 15% gain tomorow.
Good luck
Loonley tunes
Before you buy something do a good DD and make your own conclusions. My post express only my oppinion.
For now with volume under 300k look much better imo.
Hope that in near future VIVK will climb with 10% to 15% daily gains on small volume ... This will be imo the best thing for VIVK at that point ...
Good luck
Loonley Tunes
Before you buy something do a good DD and make your own conclusions. My post express only my oppinion.
i dont agree. Today volume over 9M means only one thing imo and this thing is dillution. No one will sell with loss at that point.
The problem on EFIR is that for a long time it has a very low daily volume under 3M. Now 2 days in row near 10M and most of that volume is on sell side ...
Looking for a recover on a news on the deal conclusion, but realy dont know how long will be thet "several days" as stated in last pr.
I'm in EFIR at 0.008 now for over a month ... and i was a stupid not to sell with 0$ profit 2 days ago ...
Imo once volume will get under 3M we will start climbing again ...
Good luck
Loonley Tunes
Before you buy something do a good DD and make your own conclusions. My post express only my oppinion.
anyone think is a good buy at 0.046$ ?
I only hope that the dillution is over. Now we need only a real news imo
Good luck for all people stucked in VIVK.
Loonley Tunes
Before you buy something do a good DD and make your own conclusions. My post express only my oppinion.
Do you think? For now the volume is 3.5M. Maybe someone is selling who bought under 0.006.
Today's trading day on EFIR look like the news was not seen. Daily volume is about 3.5M vs 10 day average volume of 2.5M.
but i like from the today's pr especially the statments:
" ...Additional services of Chanwest and its second phase of operations include ownership of a rig available with crewing for location application. Key management has over 40 years in the oil and gas industry, including the business of oilfield service and construction. Chanwest projects approximately 2 million in gross revenues from operations over the next year. ....
" ... The Chanwest acquisition is unrelated to plans for the acquisition of a 40-year-old production and service business that was previously reported on April 15, 2010. As an update, the negotiations with this Company are steadily progressing and further news is anticipated in the next several days. ....
Good luck
Loonley Tunes
Before you buy something do a good DD and make your own conclusions. My post express only my oppinion.
I agree with Atlanta, if deal of 600k$ is true then there is any fear about BK and the offer at 0.08$ is to good to be true at that point.
Good luck to all and i hope that patience will pay us. I will not be surprised to see some huge pr in after hours today.
Loonley Tunes
Before you buy something do a good DD and make your own conclusions. My post express only my oppinion.
Imo the pps felt because of some dillution going on and because of any interest from the part of buyers.
Once this red days will be over then one green day can atract some buyers.
I have feeling that this was a week of dillution (imo about 10M new shares were added at an average pps 0.03$ this are 300.000 $) and soon or later we should see a pop. Hope that this 0.013 is a bottom.
My thoughts on BK: Can a company go BK after a 10 months on market?
Good luck
Loonley Tunes
Before you buy something do a good DD and make your own conclusions. My post express only my oppinion.
i really hope that someone will begin messing it in the right direction ....
i cant look at pps any more, just watching to see if some good pr will be out for tomorow.
i'm not pissed, i'm scared to death see VIVK going down. But what to do sell with 60% loss or hold and wait for better days?
I have done my dd lot of time ago when the company started to trade at 0.40$ ... then went to 0.60$ and i said to myself taht i missed it .... now have bought at 0.06$ for a run over 0.10$
I hope that patience will pay. Today volume is under 1.0 million and if dillution is going on 1M vs. 70M o/s means only 1.5% of dillution. But the pps is down over 10% this is very strange.
Once strong dillution is going on the volume should be much higher imo.
Good luck
Loonley Tunes
Before you buy something do a good DD and make your own conclusions. My post express only my oppinion.
now ARCA ask 260 at 0.026
imo ARCA ask 999 block at 0.024 will soon disapear once the 0.023 will be hitten.
Something for a future positive view:
From their last 10Q ( http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=6974288 )on page 14 and 15:
Plan of Operation
The Company plans on becoming a significant transdisciplinary biomedical/biotechnology company involved in the discovery, development, acquisition and commercialization of a broad range of biotechnology, and biomedical technologies as well as nutraceutical and molecular diagnostic technologies to improve human health.
We intend to develop, manufacture and sell directly or indirectly through collaborative partners, the following types of products:
PRODUCT/R&D PHASE/DESCRIPTION
VivaThermic Vials / Phase III / Centrifugable and autoclavable vials for cryopreservation
Cryopsy / Phase I / Device that rapidly freezes tissue specimens
VivaSight / Phase II / Digital PhotoRefractor for children's vision screening
VivAuris / Phase II / nDevice for middle ear redness detection
VivaGlobin / Phase II / Device for anemia and Cutaneous hemoglobin detection
VivaBoost / Phase III / Phytochemical rich daily dose nutraceutical beverage
VivaBlend / Phase III / Concentrated phytochemical/ antioxidant extract supplement
VivaGastroProtect / Phase I / Fruits and vegetables extract for the protection of digestive system
VivaCrop /Phase I / Vegetation health monitor
Clinical Sensor (CBS)/ Phase I / In vitro diagnostic device used at the point of care
SLICES / Phase II /MRI enhancement software
We also plan to continue to offer contract research and development services in molecular biology, device engineering and other areas. We commenced providing contract research and development services in the first quarter of 2008. During the first quarter 2009, we commenced sales of our VivaThermic vials and we commenced sales of VivaBlend in the second quarter of 2009. In December 2009, we entered into a license agreement with Regeneca International, Inc. (“Regeneca”) for VivaBoost whereby Regeneca obtained exclusive worldwide distribution rights in the direct-to-consumer market and has committed to purchase $5,000,000 of product over a thirty-six month period. ....
Looks like they have a lot of products in the development phase. in other way VIVK remind me MMRF who had a lot of positive news and was flat at 0.06 for lot of time(Link to 1 year chart http://stockcharts.com/h-sc/ui?s=MMRF&p=D&yr=1&mn=0&dy=0&id=p27722707303 )
Good luck
Loonley Tunes
Before you buy something do a good DD and make your own conclusions. My post express only my oppinion.
Does anyone on this board think that today in after hours any new news is possible?
this volume at 0.02 were buys or sells?
as someone has written before:
on 30. April the pr with this news was out:
Vivakor Expands Market for VivaThermic Technologies to Genetic and Stem Cell Reagent Consumables and Further Increases Revenue Outlook
.... Additionally, VivaThermic technologies are being marketed as the best bio-consumable container for biological and stem cell related reagents which must be stored in temperature controlled environments. Dr. Fuja stated, "The global market of consumables for temperature sensitive reagent shipment, handling and storage is already enormous and continues to grow." This announcement will expand upon Vivakor's recently released revenue projections for its VivaThermic division estimated at $20 million annually. ....
today's news:
Vivakor Expands Market for VivaSight Technologies to Adult Vision Care and Further Increases Revenue Outlook
.... dditionally, VivaSight technologies will be marketed as the best and most versatile vision screening devices on the market. Mr. Matt Nicosia stated, "The market for vision screening is not just limited to United States vision care. We have received significant attention through our commercialization partners for international use of the VivaSight technology for both private practice and government mandated vision care." This announcement will expand upon Vivakor's recently released revenue projections for its VivaSight division and increase the estimated market to $50 million annually. ...
if i uderstand this two news, imo means that they expect 20M$ from Vivathermic + 50M$ from VivaSight in total 70M$. Anyone understand the same?
Good luck
Loonley Tunes
Before you buy something do a good DD and make your own conclusions. My post express only my oppinion.
i have this feeling too. But todays volume is under 2M for now ... and if all this means dillution the volume in last 2 days is about 8M ... and they have about 70M o/s .. this 8M represents about 10% of dillution. So why the price has droped over 60% from 0.05? that is the question ...?
Atlanta1 are you stuck in VIVK too?
all this selling at 0.02 looks really ugly .... now i'm really scared.
i dont know who is selling at that point. And why sell? If someone has purchased shares at open market now is selling with a loss i think.
imo is mm trick, now mm HDSN has rised a bid to 0.024 to get as more as possible cheap shares imo ...
Before you buy something do a good DD and make your own conclusions. My post express only my oppinion.
I never thought to see VIVK at 0.023$ ......
i hope that is only a mm game. i'm 80k at 0.06$ and i hope to see it going up once in this month.
Good luck
Loonley Tunes
Before you buy something do a good DD and make your own conclusions. My post express only my oppinion.
on this site looks like that this today are all buys
http://ih.advfn.com/p.php?pid=trades&symbol=vivk
Buy volume: 5.776M
Sell volume 0.641M
if this is true, why then the price is falling?
Good luck
Loonley Tunes
Before you buy something do a good DD and make your own conclusions. My post express only my oppinion.
Last news on VIVK is out .... to me seems good and i hope it means green monday.
Link: http://www.globenewswire.com/newsroom/news.html?d=193601
Vivakor Announces Receipt of LOI for $600k Investment
CORALVILLE, Iowa, June 4, 2010 (GLOBE NEWSWIRE) -- Vivakor, Inc. (OTCBB:VIVK) today announced that the Company has received a letter of intent for an investment up to $600,000 from Excelsior Management. The terms of the transaction are for an investment in restricted common stock at $0.08 per share or shares registered in the current S-1 at the S-1 price of $0.23 per share.
Vivakor Chairman Matt Nicosia added this statement to the news: "This investment interest in Vivakor coincides with management's belief that the Company is currently undervalued and validates management's efforts to create value by reducing debt and increasing the viability of its technologies. We look forward to increasing the Company's value through pushing forward commercialization efforts for both VIVASLICES and VIVASIGHT."
Good luck
Loonley Tunes
Before you buy something do a good DD and make your own conclusions. My post express only my oppinion.
In the last 10Q out on 17. May for the period ended 31. March 2010
Link: http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=6963320
on page 2:
100,000,000 shares authorized 25,450,560 shares issued
on page 3 is written;
Weighted average number of shares outstanding:25,450,560
then on page 11:
At March 31, 2010, we had cash in the bank of approximately $12,900. We are
contemplating raising additional capital to finance our exploration programs. No
final decisions regarding the program or financing have been made at this time.
We did not issue any shares during the three months ended March 31, 2010.
The only thing i don't know is if they have issued shares from 31 March till today.
Good luck to all
Loonley Tunes
Before you buy something do a good DD and make your own conclusions. My post express only my oppinion.
Their last pr from May 13, today is 20 May, so one week is over:
EGPI Firecreek, Inc. Initiates Production of Oil and Gas From Its Three Well Oil Drilling Program
Successful Completion Initiates Start for Company's New Energy Producers Oil and Gas Subsidiary Unit
May 13, 2010 7:42:00 AM
SCOTTSDALE, AZ -- (MARKET WIRE) -- 05/13/10 -- EGPI Firecreek, Inc. (OTCBB: EFIR) is pleased to announce its West Texas Three Well Program with Whitt Oil and Gas is online with the McWhorter well. The Company's successful operation and production of oil and gas will now ramp up the operations of its wholly owned subsidiary, Energy Producers, Inc.
Whitt Oil & Gas, Inc., the Company's operator for its West Texas Three Well Program, has completed and begun production of both oil and gas on the McWhorter well this week. The well is continuing to improve oil and gas production as the hydraulic stimulation (FRAC) fluid is continuously being pumped off. Production levels for the McWhorter well will be closely monitored and evaluated over the next several days but early indications show better than expected production levels. The company is also pleased to report most of the rehabilitation work on its second well, the Young well, has been completed and it is expected to be online and producing within the week. The Whitt Oil & Gas Operating team has now headed out to the Boyett well, the last well for its three well work program, and expects the well to be completed, online, and producing within the next two weeks. Final completion of the Boyett well will be subject to standard job risks and weather conditions. Operations report that the initial oil and gas recovered during all rehabilitation work has been consistent with commercial expectations.
Dennis Alexander, Chairman and CEO of EGPI Firecreek, Inc., stated, "The initiation of our Energy Producer's unit with the start of oil and gas production marks a monumental day for our corporate operations. With current crude oil prices hovering around $75 a barrel and looking to go higher, our future couldn't look better as we enter the oil and gas arena." He also stated, "Now that we can officially state that we are producing oil and gas, we intend to aggressively pursue several opportunities that have recently been made available to us in order to exponentially grow our oil and gas division. Collectively, with the right amount of working capital supplementation, we expect the Company's operations of both divisions to run on all cylinders, which will allow 2010 to be our best revenue producing year in the company's history."
About EGPI Firecreek, Inc.
EGPI Firecreek, Inc. is engaged in the DOT Construction, Intelligent Traffic System markets, and oil and gas production. Other companies in the oil sector include, Exxon Mobil, Pantina Oil and Gas Inc., Frontier Oil Inc., and Cabot Oil & Gas Inc.
Safe Harbor
This release contains statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of EGPI Firecreek, Inc., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy. The words "may," "would," "will," "expect," "estimate," "can," "believe," "potential" and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond EGPI Firecreek Inc.'s ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. More information about the potential factors that could affect the business and financial results is and will be included in EGPI Firecreek, Inc.'s filings with the Securities and Exchange Commission.
FOR MORE INFORMATION ON EGPI/FIRECREEK, INC.
CONTACT:
EGPI/Firecreek Public Relations and Shareholder Information
Joe Vazquez
(754) 204-4549
Email: info@egpifirecreek.net
and the second one at 1.36pm
Vivakor Receives Reseller Distribution Agreement From VWR International LLC, a Multi Billion Dollar Global Laboratory Supply and Distribution Company, for Its VivaThermic Vials
May 3, 2010 1:36:00 PM
2010 GlobeNewswire, Inc.
CORALVILLE, Iowa, May 3, 2010 (GLOBE NEWSWIRE) -- Vivakor, Inc. (OTCBB:VIVK) announced today that it has received a reseller offer agreement from VWR LLC, a multi-billion dollar global laboratory supply and distribution company, for Vivakor's VivaThermic Vials. Vivakor's VivaThermic vials improve cryopreservation of sensitive cell types such as human stem cells.
Vivakor 's Chief Executive Officer and Chief Scientific Officer, Dr. Tannin Fuja, stated, "We are very pleased to do business with VWR International LLC as this agreement has been the culmination of over six months of review and evaluation of the VivaThermic products. VWR is a premier leader in distribution of laboratory products to biotech, academic and pharmaceutical research markets." As global demand for products supporting stem cell related markets intensifies, the potential market size for our VivaThermic vials has increased the potential revenue projections are targeted to reach in excess of $20 million annually. Dr. Fuja continued, "The estimated growth of this market will accelerate with continued private and public support for life-saving stem cell therapies and the necessary research to discover them."
About Vivakor, Inc.
Vivakor(TM) is a biomedical/biotechnology company with transdisciplinary research that develops and acquires products in the fields of molecular medicine, electro-optics, biological handling and natural and formulary compounds that extend or improve life. More information can be found about Vivakor at www.vivakor.com.
About VWR International LLC.
VWR International, LLC, headquartered in West Chester, Pennsylvania, is a global laboratory supply and distribution company with worldwide sales in excess of $3.5 billion in 2009. VWR enables the advancement of the world's most critical research through the distribution of a highly diversified product line to most of the world's top pharmaceutical and biotech companies, as well as industrial, educational and governmental organizations. With 150 years of industry experience, VWR offers a well-established distribution network that reaches thousands of specialized labs and facilities spanning the globe. VWR has 6,500 associates around the world working to streamline the way researchers across North America, Europe, and Asia stock and maintain their labs. In addition, VWR further supports its customers by providing onsite services, storeroom management, product procurement, supply chain systems integration and technical services.
For more information on VWR please visit www.vwr.com
FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements, including, but not limited to, statements regarding Vivakor's products and their related market potential. Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in Vivakor's filings with the Securities and Exchange Commission, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Vivakor undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.
CONTACT: Vivakor, Inc.
Investor Relations
c/o IME Advisors
(888) 648-8485
.. here is the yesterdays pr from 8:50 am
Vivakor Raises Its Outlook for VivaSlices Due to Increased Demand for Healthcare Cost Reduction
May 3, 2010 8:50:00 AM
2010 GlobeNewswire, Inc.
CORALVILLE, Iowa, May 3, 2010 (GLOBE NEWSWIRE) -- Vivakor, Inc. (OTCBB:VIVK) announced today that its management has expanded its revenue outlook for its VivaSlices product currently being developed due to the increasing demand for healthcare cost reduction. VivaSlices is a software technology aimed at increasing image resolution of previous generations of MRI units saving hospitals and clinics with older equipment millions of dollars in costs related to purchasing new MRI units with enhanced image resolution capacity.
Vivakor 's Chief Executive Officer and Chief Scientific Officer, Dr. Tannin Fuja, stated, "As domestic and international healthcare systems strive to cut costs, while increasing the effectiveness of care, the need for a cost savings alternatives are receiving significant attention. In particular, we believe that the global demand for the VivaSlices products will be significant as a means of improving healthcare at a reduced cost. We estimate that the market for this technology could be in excess of $300 million annually. The estimated growth of this market will accelerate with continued global demand for cost effective healthcare."
About Vivakor, Inc.
Vivakor(TM) is a biomedical/biotechnology company with transdisciplinary research that develops and acquires products in the fields of molecular medicine, electro-optics, biological handling and natural and formulary compounds, that extend or improve life. More information can be found about Vivakor at www.vivakor.com.
FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements, including, but not limited to, statements regarding Vivakor's products and their related market potential. Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in Vivakor's filings with the Securities and Exchange Commission, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Vivakor undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.
CONTACT: Vivakor Investor Relations
c/o IME Advisors
(888) 648-8485
What do you meant with fake wall? Is this positive thing or negative in options to see that baby going up.
Reading the news i dont know why was down today ... Looking at Level 2 i only see that mm want to get the bid/ask closer. This happened today only once at bid 0.27 and ask 0.28.
Thanks for advice. Jumped today in this, because the end of yesterday look strong to me. This deep was unexpected imo.
News are all positive imo.
Glta Loonley
About half year ago i made for my self a calculation on CBAI value:
Fact:
- CBAI has about 5bilion of O/S ... on google page
- USA has a population of 300M people .... natural growth rate is 0.59% (http://en.wikipedia.org/wiki/Demographics_of_the_United_States) .... which means that 0.0059*300M is about 1.77M new born
Suggestions:
- ok if you made a projection that 10% of new born child will store cord blood ... this are about 177k people every year ....
- they have to pay for storage about 100$/year.... that means that the first year they will made 17.7M of revenue ....
- 2nd year there will be 177k (from first year) + 177k(new born) ... revenue will be abour 34M .... and after 10 year there will be a revenue 177M ....
- this are very conservative calculation imo .... which include only USA population ... but imo CBAI want to go abroad to (this happened today with European partner )....
- so if 177M of revenue devided by 5 Billion shares .... there will be a revenue of 0.0345$/ share which pps is now at 0.0098 ...
- if they expands in EU which inhabitants have money to invest in cord blood of own child .... they will get 500M people more as potencial market .... if the rate remain the same ...0.6% of natural growth .... this are 3M of new borns
- and the rate of potencial investitors in blood from 10% grow to 20% .... they will have 350K of pople every year in USA and 600K fom EU .... so together about 1M people every year on rate 100$/year ...
- this means 100M $ of revenue every year, 2nd year 200M, 3rd year 300M .... in 10 years a anual revenue will be 1Bilion ... divided by 5Billion O/S .... 0.2$ of revenue .... profit margin suppose 40% ....this are 0.08$ of EPS ....
- if we predict a PE of 10 .... this is 0.80$ .... this seems realistic in 10 years ...
What do you think about this calculation?
Good luck
Loonley Tunes
Before you buy something do a good DD and make your own conclusions. My post express only my oppinion.
Today i was long (entry over a year ago at pps 0.06)and conviced that Pix will pass the panel. When i saw that the panel voted 9 vs. 0 against Pix all i have in my mind was an exit point over 0.40$.
I will try to be onest. Reasons why i had left the CTIC train:
1. I looked back on DNDN. The first time in 2007 the Advisory Committee voted 17 to 0 in favor of the safety of PROVENGE in response to the question and 13 to 4 in favor of the efficacy question. ... few weeks later the FDA has requested additional clinical data in support of the efficacy claim contained in the BLA. The pps went down from 19$ to 6$ ... then flat for 2 years!!
Link ( http://www.reuters.com/finance/stocks/keyDevelopments?symbol=DNDN.O&pn=4 )
2. I was scared to death of the shareholders meeting on 9.april 2010 where the 1. point says:
"to approve an amendment to the Company’s amended and restated articles of incorporation to increase
the total number of authorized shares from 810,000,000 to 1,210,000,000 and to increase the total
number of authorized shares of common stock from 800,000,000 to 1,200,000,000; and"
Link ( http://www.celltherapeutics.com/pdf/04-09-10_proxy.pdf )
For this 2 reasons i left CTIC today.
Good luck
Loonley Tunes
Before you buy something do a good DD and make your own conclusions. My post express only my oppinion.
The more i read the 10k (http://investors.somaxon.com/secfiling.cfm?filingID=950123-10-26143 )more i think that a offer of buyout will came out soon.
From the report Page 33:
Properties
We lease approximately 2,000 square feet of space for our headquarters in San Diego, California subject to a lease arrangement that will expire in June 2010. We have no laboratory, research or manufacturing facilities. ... this June date could mean something imo
if you add the fact that the drug is aproved and the company is free of debt .... just think about it.
Good luck
Loonley Tunes
Before you buy something do a good DD and make your own conclusions. My post express only my oppinion.
For making a public offering biotech companies in most cases use good trial results to push the price higher. Once they get approval (SOMX, VNDA) they try to sell the drug to another big pharma and receive royalties. This way they get money without dilluite more.
From VNDA pr wuth deal with Novartis (http://www.reuters.com/finance/stocks/keyDevelopments?rpc=66&symbol=VNDA.O×tamp=20091012220000):
"Under the agreement, Vanda will receive an upfront payment of $200 million and will be eligible for additional payments totaling up to $265 million upon the achievement of certain development and commercial milestones for Fanapt in the U.S. and Canada. Vanda will also receive royalties on the U.S. and Canadian net sales of Fanapt. The consummation of the transaction is expected by the end of 2009"
Imo something similar can happen with SOMX.
And from last annual report you can read about the competition and other stuff.
http://investors.somaxon.com/secfiling.cfm?filingID=950123-10-26143
Good luck
Loonley Tunes
Before you buy something do a good DD and make your own conclusions. My post express only my oppinion.
Imo DNDN can not be compared to SOMX, because it had a cancer drug aproved. Better to compare SOMX with VNDA (Schizophrenia drug aproved)
VNDA went from 1$ before aproval to hod of 10$ on first day of trading. During the first day it had a 30% !!! pull back, finished at about 7.84$ ... i get scared ad i sold at 8.70$ the firs day .... The second day it went to 8.45$. Third day to 10.20$ and after the 4th day it was at 11.27$ and the 5th day it finished at 12.96$ then went down. Now is trading at 12$ range.
The chart:
http://stockcharts.com/h-sc/ui?s=VNDA&p=D&yr=0&mn=11&dy=0&id=p22366065488
Lot of stories were told about the Schizofrenia small market etc ... but in October 09 Novartis make an offer for that VNDA drug .
The whole story on VNDA
http://www.reuters.com/finance/stocks/keyDevelopments?rpc=66&symbol=VNDA.O×tamp=20090506223700
Imo there are two reasons why the price went down:
1. Good flip play during 2 days
2. Classical profit taking on friday (look at last hour .. from lod of 8.25 went to 9.35 half hour before market close and then a sell off happened.) If yesterday wasn't friday imo we will close in green.
And about insiders selling on SOMX:
http://www.mffais.com/somx
... lot shares were sold on 18.march 2010, but if you look back on VNDA, there the insiders selling happened to ...
Link on VNDA selling (you have to change the beggining date between 2009-04-11 and 2009-07-11)
http://www.mffais.com/vnda
The most important is that institutions came to buy VNDA on 31. may 09 (over 1M shares bought) on 30.june 09 and so on ... looks like taht institutions are buying at the end of month.
Now VNDA has a 76% of institution ownership .... SOMX is at 31%. And the nuber of O/S is similar VNDA 27.6M = Mrk.Cap. 324.58M vs SOMX about 24M = Mrk.Cap. 195.03M
Good luck to all
Loonley Tunes
Before you buy something do a good DD and make your own conclusions. My post express only my oppinion.
Something about Stem Tronix Inc.
links:
http://docs.google.com/viewer?a=v&q=cache:BmoVEqqdMwQJ:www.researchandmarkets.com/reports/1096074/global_stem_cell_and_advanced_technologies.pdf+StemTroniX+Inc+number+of+O/S&hl=sl&gl=si&sig=AHIEtbT9KBvc0L4WBJ4s9rUeV9Ibz4yjlA
http://www.researchandmarkets.com/reports/1096074/global_stem_cell_and_advanced_technologies_market
from last link:
The stem cell market is growing rapidly due to increasing regulatory approval and public acceptance bodies. The benefits of stem cell therapy are attracting an increasing number of patients. The product submarket for human and embryo stem cells are expected to drive the growth of the overall market. In addition, intensive R&D efforts and the increasing investments into research on stem cells therapy are soon expected to improve the efficacy of stem cell treatment. However, the high cost of the therapy may affect market growth.
The global stem cell market is estimated to be $88.3 billion by 2014, growing at a CAGR of 14.8 % from 2009 to 2014. The U.S. currently holds a 60% share of the global stem cell market; and forms an especially lucrative market for areas such as bone marrow transplantation through stem cells. This research report will help stakeholders gain a better understanding of product pricing and regulatory framework governing the dynamics of the stem cell market. The key players in the market include Osiris Therapeutics, Stem Tronix Inc., Stemcell Technologies, Genzyme Corp., Cytori, and Geron.
searching the net i found this old news from november 2008 on PWRM and StemTroniX:
http://www.drugdiscoverynews.com/index.php?newsarticle=2562
HOUSTON—Power3 Medical Products Inc. recently announced it executed a letter of intent with StemTroniX Inc., a Texas-based stem cell therapy company that specializes in research, exploration and consolidation of stem cell technologies for use in autologous adult stem cell therapies and transplantations.
The two companies are far from strangers. Dr. Ira L. Goldknopf, president and chief scientific officer of Power3 Medical, and Helen R. Park, founder and director of StemTroniX, both worked at Advanced Bio/Chem Inc.—most of the assets of which Power3 acquired in 2004. Park, for her part, went on to “other things,” she says, the most recent of which was to incorporate StemTroniX. She is also acting as interim CEO for Power3 right now.
Despite inking a deal, StemTroniX isn’t officially off the ground yet as a company, Park says. The two companies should officially be working on their adult stem cell collaboration by mid-2009, but Park felt it was wise to start her new company on the best foot with a strong deal already in place as a foundation.
“We’ll be doing adult stem cell therapy work overseas,” she notes. “We have a medical director ready to come on when the company officially starts up, and he has medical privileges in Switzerland to do adult stem cell therapy.”
One of the key reasons to team with Power3, aside from already knowing people within it, is because in addition to its diagnostic and drug target discovery work—in areas like cancer and neurodegenerative disease—the company is heavily focused on commercializing disease biomarkers and identifying protein biomarkers.
“In the stem cell therapy business, there is a huge need to know what makes the stem cells become and act like the organ they are aimed at—and those would be biomarkers,” Park explains. “I personally feel that the biomarkers on stem cells will be one of the next big markets. There is a huge market for stems cells but you have to have a way to direct them and make them be more useful, and that lies in knowing and understanding the biomarkers.”
and other news from october 2008:
http://www.biospace.com/news_story.aspx?NewsEntityId=112505
HOUSTON--(BUSINESS WIRE)--Power3 Medical Products, Inc. (OTCBB:PWRM), (www.power3medical.com), today announced that the company has executed a Letter of Intent with StemTroniX, Inc., a Texas based Stem Cell Therapy Company that specializes in research, exploration and consolidation of stem cell technologies for use in Autologous Adult Stem Cell Therapy’s and Transplantations.